News & Updates
Filter by Specialty:
New HF guideline: Quad therapy, HFmrEF, and more
Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.
New HF guideline: Quad therapy, HFmrEF, and more
04 May 2022
Narrow- vs broad-spectrum antibiotics: Which is better for older AECOPD patients?
Use of either empiric broad- or narrow-spectrum antibiotics in older patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) shows no remarkable difference in the primary outcome, reports a recent study.
Narrow- vs broad-spectrum antibiotics: Which is better for older AECOPD patients?
03 May 2022
Baricitinib may improve hair regrowth in alopecia areata
A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.
Baricitinib may improve hair regrowth in alopecia areata
02 May 2022
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.
Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
30 Apr 2022
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.
